시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
간질성 방광염 치료제 시장 규모, 점유율 및 성장 분석(약제 클래스별, 유형별, 투여 경로별, 유통 채널별, 지역별) : 산업 예측(2025-2032년)
Interstitial Cystitis Drugs Market Size, Share, and Growth Analysis, By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드 : 1758565
리서치사 : SkyQuest Technology Consulting Pvt. Ltd.
발행일 : 2025년 06월
페이지 정보 : 영문 191 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,256,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 8,488,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 9,720,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계의 간질성 방광염 치료제 시장 규모는 2023년 26억 달러로 평가되었고, 예측기간(2025-2032년)에 CAGR 5.2%를 나타내, 2024년 27억 4,000만 달러에서 2032년에는 41억 달러로 성장할 전망입니다.

간질성 방광염 치료제 시장은 통증, 절박감, 빈뇨를 일으키는 이 만성 방광질환에 대한 인식 증가와 진단의 개선에 의해 큰 성장을 이루고 있습니다. 환자의 QOL 향상을 목적으로 한 경구약, 방광내 치료제, 생물학적 제제 등 다양한 치료법이 제공되고 있습니다. 때문에 주로 증상의 완화에 중점을 두고 있어 보다 효과적인 치료제에 대한 수요가 높아지고 있습니다.

목차

서론

분석 기법

주요 요약

시장 역학과 전망

시장의 주요 인사이트

세계의 간질성 방광염 치료제 시장 규모·CAGR : 약제 클래스별(2025-2032년)

세계의 간질성 방광염 치료제 시장 규모·CAGR : 유형별(2025-2032년)

세계의 간질성 방광염 치료제 시장 규모·CAGR : 투여 경로별(2025-2032년)

세계의 간질성 방광염 치료제 시장 규모·CAGR : 유통 채널별(2025-2032년)

세계의 간질성 방광염 치료제 시장 규모·CAGR(2025-2032년)

경쟁 구도

주요 기업 프로파일

결론과 권고

KTH
영문 목차

영문목차

Global Interstitial Cystitis Drugs Market size was valued at USD 2.6 billion in 2023 and is poised to grow from USD 2.74 billion in 2024 to USD 4.1 billion by 2032, growing at a CAGR of 5.2% during the forecast period (2025-2032).

The interstitial cystitis drugs market is witnessing significant growth fueled by heightened awareness and improved diagnosis of this chronic bladder condition, which causes pain, urgency, and frequent urination. The market offers a variety of treatment modalities, including oral medications, intravesical therapies, and biologics, all aimed at alleviating symptoms and enhancing patients' quality of life. Current therapies primarily emphasize symptom relief due to the limited availability of curative options, driving the demand for more effective therapeutic agents. Advancements in diagnostics and a shift towards personalized medicine are further shaping market dynamics. Additionally, the increasing number of healthcare providers devising specialized treatment plans, coupled with a proactive patient demographic, is propelling market expansion as more individuals seek appropriate medical care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Interstitial Cystitis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Interstitial Cystitis Drugs Market Segments Analysis

Global Interstitial Cystitis Drugs Market is segmented by Drug Class, Type, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Non-steroidal Anti-inflammatory Drugs, Tricyclic Antidepressants, Pentosan Polysulfate Sodium (Elmiron), Dimethyl Sulfoxide (DMSO) and Others. Based on Type, the market is segmented into Non-ulcerative and Ulcerative. Based on Route of Administration, the market is segmented into Oral and Intravesical. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Interstitial Cystitis Drugs Market

The global interstitial cystitis drugs market is being significantly propelled by the rising prevalence and increasing rate of diagnoses of interstitial cystitis. As the number of identified cases grows, there is an escalating demand for effective treatment options for this challenging condition. Contributing factors include an aging demographic, increased awareness about interstitial cystitis, and advancements in diagnostic technologies that lead to more accurate identification of cases. Furthermore, due to the chronic nature and often ambiguous symptoms of the disease, many patients endure prolonged periods before seeking treatment, amplifying the overall need for specialized therapeutic solutions in the market.

Restraints in the Global Interstitial Cystitis Drugs Market

A major constraint in the Global Interstitial Cystitis Drugs market is the prohibitive cost of treatment options. Newer biologic drugs, in particular, tend to be quite costly, making them unaffordable for a large segment of the patient population. Despite these advanced therapies offering better health outcomes, their high price tags can restrict accessibility, especially in low-income areas or among individuals lacking sufficient insurance coverage. Consequently, many patients are compelled to utilize older, more affordable treatments that may not provide the same efficacy, further complicating the management of Interstitial Cystitis and hindering overall patient care.

Market Trends of the Global Interstitial Cystitis Drugs Market

The Global Interstitial Cystitis (IC) Drugs market is witnessing a significant trend toward personalized medicine, reflecting an evolving understanding of the disease's heterogeneous nature. As research progresses, treatments are being tailored based on individual genetic, molecular, and environmental profiles, moving away from one-size-fits-all approaches. This shift is powered by advancements in pharmacogenomics, which are expected to revolutionize therapy by aligning drug responses with patient-specific genetic markers. As healthcare systems increasingly adopt personalized strategies, the demand for targeted IC therapies is poised to grow, potentially leading to improved treatment outcomes and enhanced patient quality of life.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Interstitial Cystitis Drugs Market Size by Drug Class & CAGR (2025-2032)

Global Interstitial Cystitis Drugs Market Size by Type & CAGR (2025-2032)

Global Interstitial Cystitis Drugs Market Size by Route of Administration & CAGR (2025-2032)

Global Interstitial Cystitis Drugs Market Size by Distribution Channel & CAGR (2025-2032)

Global Interstitial Cystitis Drugs Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기